Evaluation of Double- and Triple-Antibiotic Combinations for VIM- and NDM-Producing Klebsiella pneumoniae byIn VitroTime-Kill Experiments

Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens

(2012) Zubair A. Qureshi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diverse Sequence Types of Klebsiella pneumoniae Contribute to the Dissemination ofblaNDM-1in India, Sweden, and the United Kingdom

(2012) Christian G. Giske et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe

(2012) R. Cantón et al.   CLINICAL MICROBIOLOGY AND INFECTION

In VitroInteractions of Antimicrobial Combinations with Fosfomycin against KPC-2-Producing Klebsiella pneumoniae and Protection of Resistance Development

(2011) Maria Souli et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients

(2011) S. M. Garonzik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Challenges of Antimicrobial Drug Resistance in Greece

(2011) S. Miyakis et al.   CLINICAL INFECTIOUS DISEASES

Molecular characterization of VIM-producing Klebsiella pneumoniae from Scandinavia reveals genetic relatedness with international clonal complexes encoding transferable multidrug resistance

(2011) Ø. Samuelsen et al.   CLINICAL MICROBIOLOGY AND INFECTION

Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment

(2011) O. Zarkotou et al.   CLINICAL MICROBIOLOGY AND INFECTION

Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?

(2011) G.L. Daikos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time–kill assay

(2011) Spyros Pournaras et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae

(2011) B. Bercot et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Double and Triple Bactericidal Activities of Doripenem, Polymyxin B, and Rifampin against Multidrug-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli

(2010) C. Urban et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Three Decades of  -Lactamase Inhibitors

(2010) S. M. Drawz et al.   CLINICAL MICROBIOLOGY REVIEWS

Extracellular concentrations of fosfomycin in lung tissue of septic patients

(2010) V. Matzi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection

(2010) Elizabeth B. Hirsch et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Evaluation of Antibiotic Synergy for Polymyxin B-Resistant Carbapenemase-Producing Klebsiella pneumoniae

(2010) A. Elemam et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

(2010) Karthikeyan K Kumarasamy et al.   LANCET INFECTIOUS DISEASES

Antimicrobial Resistance among and Therapeutic Options against Gram‐Negative Pathogens

(2009) James J. Rahal   CLINICAL INFECTIOUS DISEASES

An Outbreak of Infection due to β‐LactamaseKlebsiella pneumoniaeCarbapenemase 2–ProducingK. pneumoniaein a Greek University Hospital: Molecular Characterization, Epidemiology, and Outcomes

(2009) Maria Souli et al.   CLINICAL INFECTIOUS DISEASES

Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation

(2009) A. Michalopoulos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Clinically significant carbapenemases: an update

(2009) Timothy R Walsh   CURRENT OPINION IN INFECTIOUS DISEASES